Applied DNA Sciences, Inc. (APDN)
NASDAQ: APDN · Real-Time Price · USD
4.830
+0.315 (6.98%)
At close: Jun 27, 2025, 4:00 PM
4.900
+0.070 (1.45%)
After-hours: Jun 27, 2025, 7:10 PM EDT
Applied DNA Sciences Employees
As of September 30, 2024, Applied DNA Sciences had 48 total employees, including 46 full-time and 2 part-time employees. The number of employees decreased by 7 or -12.73% compared to the previous year.
Employees
48
Change (1Y)
-7
Growth (1Y)
-12.73%
Revenue / Employee
$78,971
Profits / Employee
-$962,233
Market Cap
2.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APDN News
- 10 days ago - Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward - Accesswire
- 11 days ago - Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August - Accesswire
- 4 weeks ago - Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 - Accesswire
- 6 weeks ago - Applied DNA Reports Second Quarter Fiscal 2025 Financial Results - Accesswire
- 6 weeks ago - Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3 - Accesswire
- 2 months ago - Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA - Accesswire
- 2 months ago - Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Accesswire
- 3 months ago - Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement - Accesswire